University of Kansas Medical Center Research Institute Inc. — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$518,525	103
2024	Research	$1,073,410	276
2023	Research	$586,852	250
2022	Research	$354,658	137
2021	Research	$32,241	12

Breakdown

Who paid Research payments · program years 2021–2025

Insmed, Inc. $1,254,778 633 payments
Kite Pharma, Inc. $665,184 122 payments
Gilead Sciences, Inc. $608,654 10 payments
EMD Serono, Inc. $32,241 12 payments
Amgen Inc. $4,829 1 payment

Studies the money was for Research payments · program years 2021–2025

A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact $784,768 350 payments
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) $277,092 122 payments
A Phase II Open-Label Study of Sacituzumab govitecan in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma $212,000 1 payment
A Phase II Open-Label Study of Sacituzumab govitecan in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma $212,000 1 payment
A Phase II Open-Label Study of Sacituzumab govitecan in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma $171,614 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study $110,469 131 payments
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma $65,494 1 payment
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma $53,967 1 payment
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) $46,115 1 payment
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma $31,928 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.